We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

127 hedge funds and large institutions have $88.4M invested in Arbutus Biopharma in 2022 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

56% more call options, than puts

Call options by funds: $1.95M | Put options by funds: $1.25M

36% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 33

12% more funds holding

Funds holding: 113 → 127 (+14)

1.29% more ownership

Funds ownership: 29.8% → 31.09% (+1.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

26% less capital invested

Capital invested by funds: $119M → $88.4M (-$30.7M)

Holders
127
Holders Change
+14
Holders Change %
+12.39%
% of All Funds
2.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
20
Increased
45
Reduced
33
Closed
5
Calls
$1.95M
Puts
$1.25M
Net Calls
+$696K
Net Calls Change
-$1.48M

Top Buyers

1
TSC
Two Seas Capital
New York
+$5.07M
2
OMC
Oasis Management Company
Cayman Islands
+$2.42M
3
Marshall Wace
Marshall Wace
United Kingdom
+$925K
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$691K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$529K

Top Sellers

1
BC
Brookfield Corp
Ontario, Canada
-$5.19M
2
Millennium Management
Millennium Management
New York
-$1.53M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$533K
4
Simplex Trading
Simplex Trading
Illinois
-$209K
5
Goldman Sachs
Goldman Sachs
New York
-$189K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
101
Ameritas Investment Partners
Nebraska
$11K – – –
CT
102
Cambridge Trust
Massachusetts
$10K – – –
SPIA
103
Steward Partners Investment Advisory
New York
$10K – – –
QCG
104
Quadrant Capital Group
Ohio
$10K +$12.7K +5,401 New
Nisa Investment Advisors
105
Nisa Investment Advisors
Missouri
$9K -$5.65K -2,400 -39%
Barclays
106
Barclays
United Kingdom
$9K -$1.98K -841 -16%
CG
107
Cutler Group
California
$9K -$956 -406 -8%
Citigroup
108
Citigroup
New York
$7K -$14.5K -6,170 -64%
PMFA
109
Plante Moran Financial Advisors
Michigan
$4K – – –
PGAM
110
Princeton Global Asset Management
New Jersey
$4K – – –
BBPWM
111
Blue Bell Private Wealth Management
Pennsylvania
$3K – – –
National Bank of Canada
112
National Bank of Canada
Quebec, Canada
$3K – – –
CUAMC
113
China Universal Asset Management Company
China
$3K +$3.31K +1,404 New
S
114
SignatureFD
Georgia
$2K +$2.61K +1,108 New
FDCDDQ
115
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.53K – – –
PA
116
Parallel Advisors
California
$1K -$398 -169 -24%
Allspring Global Investments
117
Allspring Global Investments
North Carolina
$1K – – –
Daiwa Securities Group
118
Daiwa Securities Group
Japan
$1K – – –
GWSG
119
GPS Wealth Strategies Group
Colorado
$1K – – –
HFS
120
Hantz Financial Services
Michigan
$1K – – –
HIA
121
Harbor Investment Advisory
Maryland
$1K – – –
TWA
122
TCI Wealth Advisors
Arizona
$1K – – –
TF
123
TimeScale Financial
Massachusetts
$1K – – –
CS
124
Credit Suisse
Switzerland
$1K +$1.46K +618 +61,800%
Bank of Montreal
125
Bank of Montreal
Ontario, Canada
$707 -$19.9K -8,459 -3%
2 3 4
5
6

ABUS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2022, worth a combined $88.4M — down 26% from $119M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ABUS positions and 5 closed out — a net gain of 15 holders — while 45 added to existing stakes and 33 trimmed.

The largest buyer was Two Seas Capital, adding an estimated $5.07M. The largest seller was Brookfield Corp, exiting entirely with an estimated $5.19M sold.

  • 127 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2022, up from 113 in Q2 2022.
  • Funds reported $88.4M of Arbutus Biopharma stock for Q3 2022, down 26% quarter-over-quarter.
  • 20 funds opened new Arbutus Biopharma positions in Q3 2022 and 5 closed out, a net change of +15 holders.
  • The largest Arbutus Biopharma buyer in Q3 2022 was Two Seas Capital, an estimated $5.07M added.
  • The largest Arbutus Biopharma seller in Q3 2022 was Brookfield Corp, an estimated $5.19M sold.

Based on aggregated 13F filings for Q3 2022.